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Work with human speciﬁc viruses will greatly beneﬁt from the use of an in vivo system that provides
human target cells and tissues in a physiological setting. In this regard humanized mice (hu-Mice) have
played an important role in our understanding of viral pathogenesis and testing of therapeutic
strategies. Limitations with earlier versions of hu-Mice that lacked a functioning human immune
system are currently being overcome. The new generation hu-Mouse models are capable of multi-
lineage human hematopoiesis and generate T cells, B cells, macrophages and dendritic cells required for
an adaptive human immune response. Now any human speciﬁc pathogen that can infect humanized
mice can be studied in the context of ongoing infection and immune responses. Two leading humanized
mouse models are currently employed: the hu-HSC model is created by transplantation of human
hematopoietic stem cells (HSC), whereas the BLT mouse model is prepared by transplantation of human
fetal liver, thymus and HSC. A number of human speciﬁc viruses such as HIV-1, dengue, EBV and HCV
are being studied intensively in these systems. Both models permit infection by mucosal routes with
viruses such as HIV-1 thus allowing transmission prevention studies. Cellular and humoral immune
responses are seen in both the models. While there is efﬁcient antigen speciﬁc IgM production, IgG
responses are suboptimal due to inefﬁcient immunoglobulin class switching. With the maturation of T
cells occurring in the autologous human thymus, BLT mice permit human HLA restricted T cell
responses in contrast to hu-HSC mice. However, the strength of the immune responses needs further
improvement in both models to reach the levels seen in humans. The scope of hu-Mice use is further
broadened by transplantation of additional tissues like human liver thus permitting immunopathogen-
esis studies on hepatotropic viruses such as HCV. Numerous studies that encompass antivirals, gene
therapy, viral evolution, and the generation of human monoclonal antibodies have been conducted with
promising results in these mice. For further improvement of the new hu-Mouse models, ongoing work
is focused on generating new strains of immunodeﬁcient mice transgenic for human HLA molecules to
strengthen immune responses and human cytokines and growth factors to improve human cell
reconstitution and their homeostatic maintenance.
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Mice have long been indispensable in infectious disease research
by contributing a great deal to our understanding of disease
pathogenesis and in developing prophylactic and therapeutic
approaches. However since they differ evolutionarily in many aspects
from humans, many important knowledge gaps still exist in translat-
ing the results to humans. In this regard, use of macaques has been
invaluable for deriving more relevant comparative preclinical data
with human pathogens that can productively infect these animals
(Voevodin and Marx, 2009). The high cost associated with using
these animals limits their use in large numbers and their inability to
fully mimic some disease manifestations necessitates alternative
approaches. In this regard, hu-Mice that harbor functional human
cells in a physiological setting offer tremendous advantages for
studying various human pathogens (Shultz et al., 2007). Studies
employing these novel mice are likely to bridge the gap that exists
between the results obtained from macaque studies to those seen in
the natural human host. Hu-Mice are created by transplanting
human cells or tissues into immunodeﬁcient mice that accept human
grafts without rejection. The engrafted human cells occupy relevant
physiological niches, continue to function normally and provide
ideal substrates for infection and proliferation of human pathogens
thus providing a more dynamic setting compared to in vitro experi-
mentation. Following infection, the pathogen can spread in vivo to
different organ systems and elicit appropriate responses both at the
cellular and whole organismal levels, allowing human immune
responses and associated immunopathologies to be aptly studied
(Shultz et al., 2007; Berges and Rowan, 2011; Nischang et al., 2012).
During the last 25 years numerous advances have been made in the
creation and exploitation of humanized mice for infectious disease
research (Mosier, 2000; Jamieson and Zack, 1999; Shultz et al., 2007;
Berges and Rowan, 2011; Nischang et al., 2012). Many knowledge
gaps are beginning to be ﬁlled with the derivation of promising data
with direct relevance for clinical studies. First and foremost, hu-Mice
are currently put to use to study human speciﬁc pathogens such as
HIV-1 and EBV that only infect humans in a natural setting. Second,
human speciﬁc immune responses enable identiﬁcation of the immu-
nogenic epitopes that trigger the human immune system versus that
of murine or non-human primates. These two elements shed light on
the complex picture of human pathophysiology and immunopatho-
genesis. This brief review is focused on presenting a summary of the
recent improvements in humanized mouse models using representa-
tive virus examples and highlighting comparative aspects.
Evolution of immunodeﬁcient mouse strains for human cell
engraftment
A common feature for all humanized mouse models is trans-
plantation of human cells/tissues by various routes into immu-
nodeﬁcient mice that are receptive to xenografts without graftrejection. Gradual evolution and improvements in the derivation of
immunodeﬁcient mouse strains permitted generation of new and
more complex humanized mouse models (Shultz et al., 2007). Nude
mice, while lacking T cells and consequently having defects in T cell
responses, still harbored mouse B cells and NK cells and thus were
not permissive for lasting human cell reconstitution. The availability
of severe combined immunodeﬁciency (SCID) mice lacking both T
and B cells permitted creation of hu-PBL-SCID and SCID-hu-mouse
models. Later derivation of NOD-SCID mice with lower levels of NK
cells and additional innate immune defects allowed higher levels of
human cell engraftment but were still far from ideal. A major
breakthrough in this area was the targeted disruption of the murine
IL-2 receptor common gamma chain (IL2-Rgc) gene. This gene
encodes the common and essential signaling component for the
action of cytokines IL-2, IL-4, IL-7, IL-9, IL- 15 and IL-21 (Shultz et al.,
2007; Ito et al., 2008). Disruption of IL-7 and IL-15 signaling blocks
native mouse NK cell development thus permitting enhanced human
cell engraftment. This IL2-Rgc mutation, when selectively bred
together with SCID, NOD, RAG1 or RAG2 gene mutations in different
combinations yielded a variety of more severely immunocompro-
mised recipient mice to achieve far superior human cell engraftment
(Shultz et al., 2011). Rag2
/ gc/, Rag1 / gc / (denoted as RG, BRG,
DKO, or RAG DK), NOD/Shi-scid/gc / null (NOG) and NOD/SCID/gc/
(NSG) mice are among some of these which are currently being used.
Of these, NOG and NSG mice are similar with the minor difference
being the nature of the common gamma chain disruption wherein
the NSG mice have a full null phenotype and the NOG mice have
disruption of the cytoplasmic tail of the molecule. Further improve-
ments are now focused on introducing human HLA Class I and II
immune system and cytokine genes to generate new transgenic mice
on the above genetic backgrounds to permit improved engraftment
and generate more robust human cellular and humoral immune
responses (see below) (Shultz et al., 2011; Willinger et al., 2011).Old and new humanized mouse models
A variety of hu-Mice are currently employed in virus research
based on the speciﬁc pathogen studied, experimental needs and
ease of preparation (Berges and Rowan, 2011; Nischang et al.,
2012). Various human cells and tissues are engrafted into different
immunodeﬁcient mouse strains, each with its own advantages and
disadvantages. A major advancement with the new hu-Mouse
models over the older versions is their capacity for generating
primary human immune responses. These models are summarized
in Table 1 with a broad description provided below.
hu-PBL mice
These are created by reconstitution with human mature PBMCs
by intraperitoneal (i/p) route into SCID mice (Mosier, 2000).
Table 1
Summary of old and new humanized mouse models.
Model Method/Mice used Advantages Disadvantages Viruses/Antigens studied Primary immune
response
hu-PBL i/p injection of
human PBMC.
SCID, NOD-SCID,
NSG, NOG.
Easy to prepare.
Immediate use.
Good T cell engraftment.
No multilineage
hematopoiesis.
No primary immune
response.
Graft versus host disease.
HIV-1, EBV, Measles No
hu-HSC Intrahepatic injection of
CD34þ HSC into neonates.
Intravenous injection of
CD34þ HSC into adults.
Rag1/ gc/ , Rag2/
gc/ , NSG, NOG.
Easy to prepare.
Multilineage
hematopoiesis.
Primary immune
response.
Mucosal engraftment.
No human HLA restriction. HIV-1, Dengue, EBV, HBV,
HCV, Hib vaccine, HSV-2,
Salmonella typhi, Tetanus
toxoid
Yes: humoral and cellular.
IgM, weak IgG.
No human HLA T cell
Restriction.
SCID-hu Co-implantation of human
fetal liver and thymic
fragments under kidney
capsule.
SCID or NOD-SCID.
Abundant T cell
lymphopoiesis.
Surgery needed.
Requires human fetal
tissue.
No multilineage
hematopoiesis.
No primary immune
response.
Poor peripheral T cell
engraftment.
HIV-1, CMV, EBV, HHV6,
HSV-1, HTLV-1, KSHV, VZV
No
BLT Co-implantation of human
fetal liver and thymic
fragments under kidney
capsule with additional i/v
injection of autologous
CD34þ HSC.
Rag1/ gc/ , Rag2/
gc/ , NOD-SCID, NSG.
Multilineage
hematopoiesis.
Primary immune
response.
Mucosal engraftment.
Presence of human
thymus.
Human HLA T cell
restriction.
Surgery needed.
Requires human fetal
tissue.
HIV-1, Dengue, EBV,
TSST1, WNV envelope,
DNP-KLH
Yes: humoral and cellular.
IgM, weak IgG.
Human HLA T cell
restriction.
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engraftment. The passively transferred human immune cells per-
sist for several weeks and are capable of effector functions to a
certain extent. They can be productively infected by hematopoietic
cell tropic viruses such as HIV-1. Human memory B cells continue
to generate antibodies from prior antigen exposure. However,
there is no de novo multilineage human hematopoiesis, and
consequently, no primary immune response. Graft versus host
disease (GVHD) by the injected T cells is a drawback. This model
is very appropriate for studying xeno-GVHD (Shultz et al., 2011).
SCID-hu mice
Surgical co-implantation of human fetal thymus and liver
(containing hematopoietic stem cells) fragments under the SCID
mouse renal capsule is performed to generate mice that harbor a
functional human thymus (denoted as thy/liv organoid) (McCune,
1996). There is vigorous thymopoiesis with generation of human
thymocytes and naive T cells. However, mature T cells are
conﬁned predominantly to the thy/liv organoid with poor per-
ipheral circulation. These mice are unable to generate a human
immune response due to the lack of a full spectrum of immune
cells. Nevertheless, these models have been instrumental in the
study of key aspects of viral pathogenesis with viruses such as
HIV-1 and HTLV-1 and have laid the foundation for the generation
and continued improvements of current humanized mouse mod-
els (Jamieson and Zack, 1999).
hu-HSC mice
Transplantation of hematopoietic stem cells (HSC) into a variety
of immunodeﬁcient mice by various routes is employed to generatehu-HSC mice. This model has evolved substantially over the years
(Legrand et al., 2009). Early versions involved injection of hematopoi-
etic progenitor cells (CD34þHSC, also termed SCID repopulating cells
or SRC) into conditioned adult NOD-SCID mice by intravenous (i/v) or
intra-femoral (i/f) routes. While there is de novo lymphopoiesis, T cell
development is poor. Use of new generation IL-2 gc / mice such as
RG, NOG or NSG mice led to better human cell engraftment. Two
versions of hu-HSC mice with distinct preparations currently exist,
though with important differences. The ﬁrst version calls for injection
of HSC into adult irradiated NSG/NOGmice. Although cells of multiple
hematopoietic lineages are generated, the yield of T cells is poor. The
second, improved version is intrahepatic injection of HSC into condi-
tioned newborn RG, NSG or NOGmice resulting in far superior human
cell engraftment with generation of a full complement of T cells, B
cells, macrophages, NK cells and dendritic cells (Berges and Rowan,
2011; Shultz et al., 2011). Infection of either version of these mice
with different pathogens or immunization with different antigens
gives rise to human immune responses (see below). There is also good
mucosal human cell engraftment in neonatally transplanted mice
permitting HIV-1 infection by mucosal routes (Berges et al., 2008).
BLT mice
This model is a slight modiﬁcation of the earlier SCID-hu
mouse model and a notable improvement. The acronym derives
from transplantation of bone marrow, liver and thymus (BLT), the
chief difference with the SCID-hu mouse model being the addi-
tional reconstitution with autologous HSC puriﬁed from the same
fetal liver source (Lan et al., 2006; Melkus et al., 2006). The
original BLT version used NOD-SCID mice while newer improved
versions use NSG, NOG or RG mice (Biswas et al., 2011; Stoddart
et al., 2011). Human cell engraftment with multilineage
Fig. 1. Schematic for generation of hu-HSC RG (Rag-hu) and BLT mice.
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cells is seen, as well as appropriate human T cell education and
restriction, due to the presence of an autologous human thymus.
hu-Liver-HSC mice
The above hu-Mouse models are restricted to human immune
cell/tissue reconstitution with de novo generation or maintenance
of human immune cell subsets. Hu-Mice bearing other human
tissues can also be generated to permit infection with other human
speciﬁc pathogens that have a predilection to infect organ systems
such as the liver (uPA/SCID and RG Fah
 /
mice) (Meuleman and
Leroux-Roels, 2008; Zhou et al., 2012). This further broadened their
application in infectious disease research. Novel transgenic mice
that simultaneously permit human hepatocyte and HSC engraft-
ment were recently developed to generate RG AFC8-hu HSC/Hep-
hu mice. These mice are susceptible to infection with HCV and give
rise to human speciﬁc immune response (Washburn et al., 2011).
hu-Mice preparation, infection and immunization: An
overview
A general outline for creating hu-HSC and BLT hu-Mice is
presented in Fig. 1. The following description summarizes some
important aspects of the preparation of various versions of
hu-Mice and their application for viral infection and immuniza-
tion studies. The easiest version of hu-Mice to generate is hu-PBL
mice. Adult mice, such as NSG mice, are injected i/p with 2.0107
PBMC enriched from human blood (Mosier, 2000). The mice can
be used immediately for various purposes that include viral
infections and newer protocols evaluating the effector functions
of designer T cells with engineered T cell receptors. Preparation of
hu-HSC mice involves injection of human CD34þ hematopoietic
progenitor cells (a heterogeneous population of which approxi-
mately 1% are believed to be HSC) derived from different sources
such as cord blood, bone marrow, cytokine mobilized peripheralblood or human fetal liver. Of these, the efﬁciency and duration of
engraftment appear to be better with the fetal liver derived CD34þ
cells due to their more primitive lineage development status.
Compared to SCID-hu mice and BLT mice, preparation of hu-HSC
mice is not technically intensive, as no surgery is involved. Immuno-
deﬁcient mouse strains, namely RG, NOG or NSG, are commonly used
(Traggiai et al., 2004; Berges et al., 2006; Becker et al., 2010;
McDermott et al., 2010; Akkina et al., 2011; Shultz et al., 2011).
Injection of HSC into neonatal mouse livers within 3 days of birth
versus adult mice gives far superior engraftment, with generation of
human immune competent mice that harbor the four essential
immune cell subsets, namely T cells, B cells, macrophages and
dendritic cells. The following protocol is routinely used in our
laboratory and yields well engrafted mice. Fragments of human fetal
liver (16–20 weeks gestation) are subjected to enzymatic digestion
with collagenase, DNase and hyaluronidase to prepare a single cell
suspension. The cells are incubated with anti-CD34 antibody and
enriched by immunomagnetic bead-based positive selection. The
purity of CD34þ cells generally ranges between 90 and 99% after
two successive cycles of selection. The puriﬁed cells are cultured
overnight in a human cytokine media mix containing IL-3, IL-6 and
SCF. Freshly puriﬁed cells are preferred although previously frozen
cells can also be used. The neonatal mice are conditioned by
irradiation at 350 rads 2–24 h prior to cell injections. We routinely
use 5105 human fetal liver derived CD34þ cells per mouse pup to
ensure consistent engraftment, although fewer cells can be used, in
which case the duration of engraftment may be shorter due to lower
numbers of true hematopoietic stem cells. A 30 mL volume of cells is
injected intrahepatically by visualizing the dark area occupied by the
liver under the relatively transparent skin (Fig. 2). Post-manipulation,
pups are returned to their mothers in BSL-2 conditions and weaned
3 weeks later. The engrafted mice are screened to determine the
levels of human CD45þ cells in peripheral blood at around 12
weeks of age. On average we obtain mice with 40–90% human cell
engraftment. Human cell engraftment is seen in primary and
secondary lymphoid organs, as well as mucosal engraftment in the
Fig. 2. Intra-hepatic injection of CD34þ hematopoietic stem cells (HSC) into
newborn RG mouse.
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transmission (Berges et al., 2008). In general 20–30 hu-HSCmice can
be made with a typical batch of fetal liver derived CD34þ cells.
With regard to the preparation of BLT mice, original reports used
NOD-SCID mice (Lan et al., 2006; Melkus et al., 2006; Denton and
Garcia, 2011). More recent protocols use NSGmice due to far superior
engraftment (Biswas et al., 2011; Denton et al., 2012; Marsden et al.,
2012). Adult mice are conditioned by sub-lethal whole body irradia-
tion at 325 rads prior to human tissue transplantation. Human fetal
thymic and liver tissues (16–22 weeks gestation) are dissected into
1mm fragments and introduced together by the use of a trochar
under the left kidney capsule of anesthetized mice. Each of the mice
is later injected (i/v, tail vein) with 2.5105 autologous CD34þ HSC
puriﬁed from the remaining fetal liver. The transplanted mice are
evaluated for human cell engraftment at 7–12 weeks before their use
for various experiments. In practice, 15–20 mice can be made with a
typical set of fetal tissues. Preparation of SCID-hu mice is similar to
that of BLT mice with the exception that no CD34þ cells are injected
after implantation of thymus and liver tissues and the mice are not
irradiated.
Viral pathogens such as HIV-1, dengue and EBV have been more
commonly studied in these new hu-Mouse models (Van Duyne et al.,
2009; Berges and Rowan, 2011; Ramer et al., 2011). The most
common route of experimental infection with HIV-1 is via the i/p
route, which typically involves use of either the CCR5-tropic viral
strain BaL or the CXCR4-tropic strain NL4-3 (1105 i.u) (Berges
et al., 2006). Viremia is seen within one week and infection can
persist life-long based on the maintenance of human cell engraft-
ment, which in turn depends on the quality of the HSCs injected
(Berges et al., 2010). Viral inocula (1106 i.u.) are delivered by i/p,
subcutaneous (s/c) or intradermal (i/d) routes for dengue infection
(Kuruvilla et al., 2007; Jaiswal et al., 2012). Mice develop acute
viremia generally lasting for three weeks. With EBV, 1105–1106
RIU are injected i/p (White et al., 2012). In addition to infection with
live viruses, a variety of antigens have been used for experimental
immunizations that include tetanus toxoid (TT), HBV, HIV-1 and
West Nile virus envelop antigens, among others (Traggiai et al.,
2004; Berges and Rowan, 2011; Becker et al., 2010; Biswas et al.,
2011). The immune response onset is slow in these mice and takes
longer to peak, generally around 4–10 weeks.Humoral immune responses in hu-Mice
Several reports documented antigen-speciﬁc human antibody
responses in hu-HSC mice (Matsumura et al., 2003; Traggiai et al.,
2004; Ishikawa et al., 2005; Gorantla et al., 2007; Kuruvilla et al.,2007; Watanabe et al., 2007; Shultz et al., 2010; Garcia and
Freitas, 2012). While both IgM and IgG responses were reported
by different investigators, in general, IgG responses were found to
be somewhat weak. Antibody repertoire in hu-HSC RG mice by
analysis of the length of the CDR3 hypervariable regions revealed
that the human IgM B cell repertoire was akin to that of normal
healthy individuals thus indicating no obvious limitations to
generate human antibodies of various speciﬁcities (Becker et al.,
2010). However, TT and HBV vaccine immunizations of hu-HSC
RG mice gave a predominantly IgM response with limited antigen
speciﬁc IgG production, thus indicating a general failure to class
switch. Given that these mice do accumulate total serum IgG
efﬁciently, the paucity of antigen speciﬁc IgG is puzzling. One
study employed PBMC transfected with a human TCR speciﬁc for
inﬂuenza HA peptide and bearing a matched HLA with that of
Hu-Mice prepared with matched HSC. When these T cells were
passively transferred into the respective mice and antigen chal-
lenged, there was an increase in total IgG indicating that the
isotype switch deﬁciency is not due to an intrinsic defect in the B
cells but rather an impairment in T cell cooperation (Watanabe
et al., 2009). This can be attributed to human T cell restriction by
murine MHC in addition to a potential T cell dysfunction. When
IgDþ CD19þ naive B cells from hu-HSC mice were treated
in vitro with anti-CD40 antibodies, IL-2, and IL-21 in the presence
of antigen they became activated and secreted IgG, again con-
ﬁrming the functionality of B cells in these hu-HSC mice. In
substantiating human HLA restricted T cell help, another study
using HLA-DR4 (MHC Class II) transgenic mice and reconstitution
with matching HSC reported improved immune responses with
higher levels of IgG production with efﬁcient class switching
(Danner et al., 2011). A more recent phenotypic analysis of B cells
derived from hu-HSC mice generated using adult NSG mice
revealed a normal B cell developmental pathway (Chang et al.,
2012). Molecular analysis of single B cells however indicated that
while the overall distribution of Vh genes reﬂected a normal
human antibody repertoire, mature B cell subsets showed auto-
immune characteristics (Chang et al., 2012). The wide variations
seen in hu-HSC mice with regard to antibody production and class
switching could be attributed to a number of factors, including a
lack of proper human T cell restriction and help, as well as
differences in protocols, i.e., utilizing neonatal mice versus adult
mice for HSC transplantation or using different HSC sources,
namely cord blood and fetal liver. Nevertheless, additional
improvements of hu-HSC are necessary as discussed below.
Conventional SCID-hu mice have been modiﬁed to generate BLT
mice and thus provide a more appropriate thymic microenviron-
ment for human T cell development and improved T/B cell
cooperation (Lan et al., 2006; Melkus et al., 2006). This resulted
in a more robust T cell development in addition to the generation
of B cells, macrophages and dendritic cells. Positive and negative
selections of T cells are expected to occur in the autologous
human thymus during their maturation. Mature T cells in these
mice were shown to generate MHC class I and II restricted
human immune responses and offer T cell help to the antigen
stimulated B cells (Melkus et al., 2006; Tonomura et al., 2008).
A number of early studies in BLT mice have shown both IgM
and IgG antigen speciﬁc responses, albeit with varied robust-
ness (Melkus et al., 2006; Berges and Rowan, 2011). However a
subsequent study failed to show antigen speciﬁc IgG responses
despite repeated booster immunizations (Rajesh et al., 2010).
This is attributed to a lack of optimal conditions for germinal
center formation and Ig class switching. A recent study evaluated
BLT mice more in depth to determine the antigen speciﬁc
antibody responses by immunization with adjuvanted HIV-1
and WNV envelop antigens (Biswas et al., 2011). Marked differ-
ences were noted both in terms of B cell composition and
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repeated booster immunizations did not result in secondary
responses characterized by the production of IgG. In contrast to
the human, an abundance of a ‘‘B-1 like’’ B cell population
(CD19þCD5þ) was noted. The predominant IgM antibody response
and lack of IgG is attributed to the CD5þ B cell subset believed to
be responsible for production of ‘natural antibody‘ using a T cell
independent pathway.hu-Mice for generation of human monoclonal antibodies
The new hu-Mouse models can be exploited to generate a
broad spectrum of antibodies, both neutralizing and non-
neutralizing since they are shown to harbor a normal human
antibody repertoire. The broad scheme would involve either
infection or vaccination with a desired antigen with or without
an adjuvant. Splenocytes containing the antigen speciﬁc B cells
can be harvested at the peak time of immune response for later
selection, expansion and immortalization. In an alternative
approach, antigen speciﬁc individual B cells can be sorted and
their antibody genes cloned for incorporation into an ectopic
expression system. Based on the desired application, speciﬁc
antibody gene sequences can also be class switched for thera-
peutic purposes using molecular techniques. Following these lines
one study achieved generation of human monoclonal antibodies
employing hu-HSC RG mice (Becker et al., 2010). Following
immunization with commercially available TT and HBC vaccines,
memory B cells expressing surface immunoglobulins were FACS
sorted from splenic and mesenteric lymph node single cell
suspensions. A retroviral vector encoding BCL6 and BCL-XL genes
was used to immortalize the sorted B cells which were cultured in
the presence of CD40L and IL-2. Culture supernatants were tested
by ELISA to identify speciﬁc antibody producing wells followed by
limiting dilution culturing to obtain monoclonal B cell lines. Only
IgM antibody-secreting B cell clones could be obtained, although
IgG responses were seen in the immunized mice albeit at lower
levels. Further improvements in hu-Mice should lead to more
efﬁcient generation of all immunoglobulin classes.Human T cell immune responses and HLA restriction
in hu-Mice
Early reports showed induction of antigen speciﬁc T cell
responses in the new generation hu-HSC mice against various
human pathogens (Hiramatsu et al., 2003; Strowig et al., 2009;
Berges and Rowan, 2011). Depletion of CD8þ T cells abrogated
the immune control of HIV-1 and EBV infection in hu-HSC mice
thus providing additional evidence for their role in protection
(Yajima et al., 2009; Gorantla et al., 2010a, 2010b). However,
other studies reported deﬁciencies in T cell responses (Baenziger
et al., 2006; An et al., 2007; Watanabe et al., 2009). Polyclonal
stimulation of hu-HSC mouse splenocytes by PHA, anti-CD3/anti-
CD28 antibodies and PMA/ionomycin, while leading to cell pro-
liferation and cytokine secretion, revealed 10-fold lower response
than was seen with human PBMC, suggesting a functional defect.
Also, human T cells responded poorly to in vivo immunizations as
shown by the lack of IFN-g or IL-4 secretion after speciﬁc antigen
re-stimulation ex vivo. Speciﬁc CD4 and CD8 responses were
measured by cytokine secretion assays, cell proliferation assays
or cytotoxic assays in vitro by restimulation of cells from mice
infected with either HIV-1 or EBV. Even in reports showing
immune activity, the responses are low. These suboptimal
responses are attributed to several factors. First is the overall
low level of T cells in these mice, which is believed to result froma potential lymphopenia-induced T cell activation among other
causes (Garcia and Freitas, 2012). Second, lower levels of T cells in
hu-HSC mice is also thought to be due to a lack of human HLA
restriction, since T cell selection is happening in the xenogenic
mouse thymic environment in a H-2 restricted fashion, which is
likely not efﬁcient for human cells. Third, T cells generated also
exhibit poor survival in the periphery as a result of their less than
optimal interactions with mouse APCs and weak signaling (Garcia
and Freitas, 2012). In support of these possibilities, it was recently
reported that when RG mice transgenic for HLA-DR4 were
reconstituted with matching HLA-DR4 CD34þ cord blood cells,
there was a drastic elevation in the numbers of thymic and
peripheral T cells (Danner et al., 2011). Shultz et al. generated
Class I HLA-A2 transgenic mice and reconstituted them with
matched HSC (Shultz et al., 2010). These mice were shown to be
capable of HLA restricted cellular immune responses to EBV.
Based on these ﬁndings it is now evident that forced expression
of HLA-A2 and HLA-DR4 enables HLA restricted T cell functions
correlating with improved cytokine secretion and IgG production.
T cell responses in BLT mice are found to be qualitatively normal
due to reconstitution with autologous human thymus and HSC
thus permitting HLA restriction of T cell responses and more
efﬁcient T and B cell interactions. In a recent study HIV-1
infection in BLT mice gave rise to epitope speciﬁc anti-viral
responses in a class I restricted manner (Dudek et al., 2012).
Antigen speciﬁc CD8þ T cell responses were found to mimic
those in humans in terms of their speciﬁcity, kinetics and
immunodominance. It was also found that mice expressing the
particular HLA class allele HLA-B 57 exhibited enhanced control of
HIV-1 infection as seen in humans that bear the same allele.Human pathogens and other antigens studied in hu-Mice
A variety of human pathogens, particularly viruses, have been
studied in new generation hu-Mice (Table 2). Of these HIV-1, EBV,
dengue and HCV are by far the most widely studied and are
discussed in more detail in sections below. Hu-Mice have also
been used to study HTLV-1 proviral integration and induction of T
cell lymphomas (Banerjee et al., 2010; Yamamoto et al., 2010;
Villaudy et al., 2011). A number of studies focused on dengue viral
infection and showed viremia with concomitant humoral and
cellular responses (Kuruvilla et al., 2007; Cox et al., 2012; Jaiswal
et al., 2012). Hu-Mice with human hepatocyte reconstitution
allowed infection with hepatotropic viruses such as HCV and
HBV inducing pathologies and immune responses (He et al., 2010;
Washburn et al., 2011). A variety of human herpes viruses have
also been studied. These reports documented HLA-restricted
adaptive T cell immune responses to EBV, CMV reactivation from
latency, protective innate and adaptive immune responses against
intravaginal HSV-2, and generating an anti-KSHV-antibody
immune response (Melkus et al., 2006; Parsons et al., 2006;
Kwant-Mitchell et al., 2009; Strowig et al., 2009; Smith et al.,
2010). More recent studies have expanded the use of hu-Mice to
other non-viral pathogens. These encompass work with drug
resistant Salmonella typhi (Libby et al., 2010; Firoz Mian et al.,
2011), persistent infection with the malaria parasite P. falciparum
(Arnold et al., 2011) and detection of hu-Mouse adaptive and
innate immune responses against Leishmania (Wege et al., 2012).
In addition to live pathogens, a number of antigens and human
vaccine preparations have also been tested to evaluate Hu-Mice
human immune responses. Immunization with DNP(23)-KLH
antigen generated human T cell proliferation and human IgG
responses (Tonomura et al., 2008). Toxic shock syndrome toxin
1 caused an expansion of human T cells and activation of human
dendritic cells (Melkus et al., 2006). Administration of a variety of
Table 2
Examples of viruses studied in new Hu-Mouse models.
Virus Research area Topic Model References
HIV CD4 T cell loss/Immune
response
CD4 depletion/Cellular NOG (Nie et al., 2009)
CD4 depletion/Cellular RG (Berges et al., 2006; An et al., 2007; Zhang et al., 2007; Baenziger
et al., 2006; Berges et al., 2010)
Cellular (CD8 depletion) NSG (Gorantla et al., 2010b)
Cellular NOK (HLA) (Sato et al., 2012)
Humoral RG (Gorantla et al., 2007)
Humoral NOG (Watanabe et al., 2007)
Cellular/Humoral NSG (Singh et al., 2012)
Cellular/Humoral NSG-BLT, NOD/
SCID-BLT
(Brainard et al., 2009)
Cellular/Humoral NOG (Sato et al., 2010)
Humoral NSG (Chang et al., 2012)
Nef and replication BLT (Zou et al., 2012)
Vpu and replication NOG (Sato et al., 2012)
Immunopathogenesis Atherosclerosis NSG (Dubrovsky et al., 2012)
Bacterial translocation RG (Hofer et al., 2010)
IFNa NSG-BLT (Long and Stoddart 2012)
pDC RG (Zhang et al., 2011)
Treg RG (Jiang et al., 2008)
Viral dissemination BLT (Murooka et al., 2012)
Neuropathogenesis Neuroinﬂammation NSG (Gorantla et al., 2010a)
Neuronal integrity NSG (Dash et al., 2011)
Latency Latency/Drug reactivation NSG-BLT (Marsden et al., 2012)
Latency NSG-BLT (Denton et al., 2012)
Latency RG (Choudhary et al., 2012)
Evolution/Immune
escape
APOBEC3-mediated mutagenesis NOG (Sato et al., 2010)
Cellular immunity escape BLT (Dudek et al., 2012)
Env mutations RG (Ince et al., 2010)
gp41 mutation NSG-BLT (Garg et al., 2011)
Transmission/
Prevention
Vectored broadly neutralizing abs NSG, RG (Balazs et al., 2012)
Broadly neutralizing antibody vaginal
microbicides/VRC01
RG (Veselinovic et al., 2012)
Antiretrovirals/Oral BLT (Wahl et al., 2012)
Antiretrovirals/Rectal and vaginal NOD/SCID-BLT (Denton et al., 2008; Denton et al., 2010)
Antiretrovirals/Vaginal NSG-BLT (Denton et al., 2011)
Antiretrovirals/Vaginal RG (Neff et al., 2010; Neff et al., 2011)
Aptamer-siRNA NSG-BLT (Wheeler et al., 2011)
Rectal transmission NOD/SCID-BLT (Sun et al., 2007)
Vaginal transmission NSG-BLT (Stoddart et al., 2011)
Vaginal and rectal transmission RG (Berges et al., 2008; Hofer et al., 2008; Akkina et al., 2011)
Antiretrovirals Nano-formulated drugs NSG (Dash et al., in press)
HAART RG (Choudhary et al., 2009; Sango et al., 2010)
Long acting drugs NOG (Nischang et al., 2012)
Novel therapeutics Aptamer, aptamer-siRNA chimera RG (Neff et al., 2011; Zhou et al., in press)
Dendrimer formulated-siRNA RG (Zhou et al., 2011)
siRNA RG (ter Brake et al., 2009)
siRNA NSG (Kumar et al., 2008)
siRNA-nanoparticles NSG-BLT (Kim et al., 2010)
Tat peptides RG (Van Duyne et al., 2008)
Gene therapy Broadly neutralizing 2G12 Ab RG (Luo et al., 2010)
Anti-CCR5 zinc ﬁnger nuclease NSG (Holt et al., 2010)
Anti-CXCR4 zinc ﬁnger nuclease NSG (Wilen et al., 2011; Yuan et al., 2012)
Anti-gag TCR NSG-BLT (Kitchen et al., 2012)
Antisense Env NSG (Mukherjee et al., 2010)
shRNA NOD/SCID-BLT (Shimizu et al., 2010)
TRIM5a isoform, CCR5 shRNA, Tar decoy RG (Walker et al., 2012)
Broadly neutralizing 2G12 Ab NSG (Joseph et al., 2010)
CMV Immune response Humoral NOD-SCID b2 M (Aspord et al., 2011)
Latency Latency activation NSG (Smith et al., 2010)
Dengue Infection/Immune
response
Humoral RG (Kuruvilla et al., 2007)
Cellular/Humoral NSG-BLT (Jaiswal et al., 2012)
Transmission Mosquito NSG (Cox et al., 2012)
Immunopathology Clinical signs NOD-SCID (Bente et al., 2005)
Clinical signs NSG (Mota and Rico-Hesse 2011)
EBV Infection/Immune
response
Cellular RG (Traggiai et al., 2004)
Tumorigenesis NSG (White et al., 2012)
Cellular NOG (Yajima et al., 2009)
Antivirals Protease inhibitor NSG (Dewan et al., 2009)
HBV Transmission Cross-species uPA/SCID (Sa-Nguanmoo et al., 2011)
Immunopathology cccDNA loss uPA/SCID (Lutgehetmann et al., 2010)
Antivirals IFNa, Ribavirin, Cyclophilin inhibitor RG Fah/ (Bissig et al., 2010)
Capsid destabilizer uPA/SCID (Brezillon et al., 2011)
HCV Immune Response Cellular RG/AFC8 (Washburn et al., 2011)
Transmission Envelope glycoprotein ﬁtness uPA/SCID (Brown et al., 2012)
Antivirals IFNa, Ribavirin, Cyclophilin inhibitor RG Fah-/- (Bissig, Wieland et al., 2010)
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Table 2 (continued )
Virus Research area Topic Model References
HSV-2 Infection/Immune
response
Cellular/Humoral RG (Kwant-Mitchell et al., 2009)
HTLV-1 Infection/Immune
response
Cellular NOG (Takajo et al., 2007)
Latency Proviral integration NOG (Yamamoto et al., 2010)
Tumorigenesis T cell development RG (Villaudy et al., 2011)
Inﬂuenza Immune response Vaccine NOD-SCID b2 M (Yu et al., 2008)
Antivirals Aminobisphosphonate RG (Tu et al., 2011)
KSHV Infection/Immune
response
Humoral NOD-SCID (Parsons et al., 2006)
Immunopathology Splenic B cell expansion NSG (Boss et al., 2011)
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inﬂuenza-speciﬁc human CD8þ T cells, human IgM antibody
responses to tetanus toxoid and HBV (Yu et al., 2008; Becker
et al., 2010). This list is only a partial representation of that
reported in the current literature which is expected to grow as the
use of these mouse models becomes more wide spread.HIV pathogenesis and latency
Since HIV-1 is a human speciﬁc virus, hu-Mice that harbor
HIV-1 susceptible cells in a physiological setting provide an
excellent in vivo experimental system. Indeed numerous studies
were conducted in the early versions that include hu-PBL and
SCID-Hu mice providing valuable data (Jamieson and Zack, 1999;
Mosier, 2000). However, a major limitation of these systems was
the lack of a full repertoire of human immune cells and a
functioning immune system, thus limiting detailed studies on
immunopathogenesis which plays a central role in disease onset.
The new hu-Mice have mostly rectiﬁed these deﬁciencies and
thus permitted many new experimentations (Legrand et al., 2009;
Berges and Rowan, 2011; Nischang et al., 2012). The hu-Mice
used consist of RG, NOG and NSG backgrounds. HIV-1 infection is
readily established by different routes that include i/v, i/p and
vaginal and rectal mucosal routes. Viremia is established gener-
ally within a week. One study using hu-HSC RG Mice showed that
chronic viremia can persist for as long as one year, thus permit-
ting long term studies in this model (Berges et al., 2010). Both
CCR5 and CXCR4 tropic as well as dual tropic viruses can readily
establish infection and there is characteristic helper CD4þ T cell
loss, which is a hallmark of HIV-1 immunosuppression. As seen in
the human, CCR5 tropic viruses preferentially deplete CD45
RA CD4þ memory T cells whereas the CXCR4 viruses quickly
deplete both CD45 RAþ naive and CD45 RA memory CD4þ
T cells (Nie et al., 2009; Berges and Rowan, 2011). HIV-1 infection
in these mice is disseminated and infected cells are seen in both
primary and secondary lymphoid organs as well as in the brain.
In addition to CD4þ T cell loss many other mechanisms have
been proposed for HIV pathogenesis (Sodora and Silvestri, 2010;
Zhang and Su, 2012). These include chronic immune activation
due to microbial translocation as a result of loss of gut integrity,
loss of regulatory T cell (Tregs), activation of pDCs and induction
of type I interferon among others. Activation of pDCs leading to
production of type I IFN and other cytokines was demonstrated
during HIV-1 infection of hu-HSC RG mice (Zhang et al., 2011).
This positively correlated with immune activation and helper
CD4þ T cell depletion. Studies in NSG-BLT mice also showed
elevated levels of IFNa and immune activation (Long and
Stoddart, 2012). Tregs (CD4þCD25þFoxP3þ) are believed to
play a central role in modulating the induction and suppressionof immune activation (Zhang and Su, 2012). With the predilection
of HIV-1 to CD4þ T cells including Tregs, paradoxical immuno-
logical consequences are predicted. For example, during HIV-1
infection Tregs can inhibit immune activation, which is beneﬁcial.
On the other hand, their suppression of T cell responses is
detrimental by preventing elimination of infected cells. Hu-HSC
RG mice were shown to harbor functional human Tregs and HIV-1
infection of these mice led to preferential infection and depletion
of Tregs during the acute phase (Jiang et al., 2008). T cell
exhaustion characterized by PD-1 upregulation during chronic
HIV-1 infection is believed to play a signiﬁcant role in reducing
the function of HIV-1-speciﬁc T cells. Upregulation of PD-1 was
observed in HIV-1 infected hu-Mice akin to that seen in humans,
thus opening new avenues for therapeutic targeting of this
inhibitory receptor using this system (Brainard et al., 2009).
Administration of monoclonal antibodies to PD-L1, the ligand
for PD-1, to chronically HIV-1 infected hu-HSC RG mice blocked
its function and resulted in decreased viral loads and increased
T cell levels giving credence to this therapeutic approach (Palmer
et al., in press).
Primary HIV-1 infection is predominantly established by CCR5
tropic virus. During disease progression X4 viruses arise in majority
of patients although their origin is not entirely clear. Hu-Mice that
support long term HIV-1 infection permit evaluation of viral evolu-
tion in vivo. A study in hu-HSC RG mice evaluated this question by
looking at the evolution of R5 tropic virus JR-CSF for 44 weeks and
found that the mean rate of viral env gene evolution is similar to that
seen in the human (Ince et al., 2010). It is well known that HIV-1
establishes latency early on during the acute phase of infection and
that these latently infected cells serve as a viral reservoir even in the
presence of HAART (Marsden and Zack, 2010). The mechanisms of
viral latency are beginning to be understood. Latently infected cells
are unrecognizable by the immune system and the silent provirus is
impervious to ART. Cessation of HAART results in viral rebound.
Current strategies are aimed at eliminating the latently infected cells
to achieve a complete cure (Archin et al., 2012). Therefore an in vivo
experimental system that mimics HIV latency in the human will be
invaluable. Towards this goal, three reports have recently demon-
strated HIV-1 latency in humanized mice (Choudhary et al., 2012;
Denton et al., 2012; Marsden et al., 2012). Using the RG mouse
system, Choudhary et al. found that HIV-1 viral loads could be
suppressed to undetectable levels by ART and cessation of treatment
led to viral rebound. After ex vivo stimulation, recoverable latent
virus was found in resting CD4þ T cells of which the majority
were of the central memory phenotype. Similar experiments
using BLT mice also demonstrated the presence of latent virus in
resting CD4þ T cells (Denton et al., 2012; Marsden et al.,
2012). Ex vivo treatment with phorbol esters prostratin and
12-deoxyphorbal-13-phenylacetate induced HIV-1 outgrowth from
these latently infected cells (Marsden et al., 2012). The ability to
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after cessation of treatment and the ability to induce the latent virus
towards productive infection employing the newer Hu-Mouse mod-
els now provides an ideal in vivo experimental system to test future
strategies of purging latently infected cells and in achieving a
complete cure for HIV disease.HIV-1 mucosal transmission and prevention
Primary infection via vaginal and rectal mucosal routes
constitutes the predominant mode of viral transmission with
HIV-1 (Denton and Garcia, 2011). With no effective HIV-1 vaccine
on the horizon, alternative preventive methods such as topically
applied microbicides or orally administered prophylactic drugs are
practical alternatives (Heneine and Kashuba, 2012; Shattock and
Rosenberg, 2012). Until recently the monkey-SIV/SHIV model has
been the gold standard for studying comparative aspects of
HIV mucosal transmission and prevention (Veazey et al., 2012).
However, since it does not employ HIV-1 itself and is expensive,
rapid progress has not been possible in these critical areas of HIV
prevention. Furthermore, it is not possible to test promising HIV-
speciﬁc compounds against the various HIV-1 strains and drug
resistant viruses that occur in the ﬁeld. Humanized mouse models
can overcome these important limitations (Denton and Garcia,
2011). In this regard, the classical SCID-hu-PBL humanized mouse
model was evaluated for early microbicide testing. However, due
to inadequate mucosal tissue engraftment by human cells, the
infection rate was found to be low and variable, and therefore the
model was not consistently reliable (D’Cruz and Uckun, 2007). The
newer hu-Mouse models have overcome these limitations (Denton
and Garcia, 2012). Both hu-HSC RG and BLT mouse models have
human cell engraftment with HIV-1 susceptible cells being present
in the female reproductive tract (Berges et al., 2008; Denton et al.,
2008). Efﬁcient and consistent HIV-1 mucosal transmission via
vaginal routes was achieved in both these models (Berges et al.,
2008; Denton et al., 2008). Based on reports that employed hu-HSC
mice, it became clear that HSC transplantation alone was adequate
to achieve human cell mucosal engraftment and that human
thymus transplantation (as done with BLT mice) is not necessary
(Berges and Rowan, 2011). Human cell engraftment is also shown
in the intestinal and rectal tracts in both the models (Sun et al.,
2007; Berges et al., 2008; Denton and Garcia, 2011), with the
exception of one report using hu-HSC RG mice (Hofer et al., 2008).
This discrepancy was later ascertained to be due to not culturing
the HSC in human cytokine media prior to transplantation as well
as insufﬁcient time allowed before evaluation (Berges and Rowan,
2011; Nischang et al., 2012). With regard to human cell engraft-
ment in BLT mice, it was found that NSG mice were far superior
compared to NOD-SCID mice with drastic differences seen in the
rates of vaginal HIV-1 transmission (Stoddart et al., 2011). How-
ever for intestinal T cell reconstitution, a recent report determined
that IL-2R gc is critical since NOD-SCID mice had better human cell
reconstitution in the gut compared to NSG mice that lack this
receptor (Denton et al., 2012). Mucosal transmission via rectal
route was achieved in both the BLT and hu-HSC RG mouse models
(Sun et al., 2007; Berges et al., 2008). Rectal abrasion was necessary
in BLT mice prior to HIV-1 challenge to achieve infection, whereas
this was not required in the case of hu-HSC RGmice. While mucosal
infection could be established with both R5 and X4 HIV-1 viral
strains, R5 virus was found to be more efﬁcient, consistent with its
predominant role in primary infections in the human. With these
new advances in hu-Mice, the dynamics of HIV-1 transmission via
mucosal routes, early virus-cell interactions and establishment of
initial infected cell foci and their later systemic dissemination can
be studied in vivo. An additional advantage with the hu-Mousemodels over that of macaques is that there is no requirement for
hormonal treatment to induce vaginal thinning prior to viral
challenge to achieve consistent infection.
Currently oral pre-exposure prophylaxis (PrEP) with RT inhibi-
tors tenofovir and emtricitabine has recently been FDA approved
based on successful clinical trials (Steinbrook, 2012). Similarly,
vaginally applied tenofovir microbicide gel was found to be
effective with an overall 39% efﬁcacy showing the promise of this
approach (Abdool Karim et al., 2012). However, protection was not
complete and a later clinical trial failed to show efﬁcacy thus
warranting detailed pharmacokinetic-phamacodynamic (PK-PD)
analysis to derive critical data. Additionally, it is also clear that
use of a single drug as a prophylactic will not be adequate given
the propensity of HIV-1 for drug resistance. These criteria form a
basis for conducting rapid experimental evaluations of numerous
promising anti-HIV compounds and biological molecules for their
prevention potential. Indeed recent studies in Hu-Mice have begun
to yield promising preclinical data. It was found that oral admin-
istration of CCR5 inhibitor maraviroc and integrase inhibitor
raltegravir can fully protect against HIV-1 vaginal challenge in
hu-HSC RG mice (Neff et al., 2010). Topical vaginal application of
maraviroc gel was also found to confer full protection against
HIV-1 vaginal transmission (Neff et al., 2011). Extending this
principle to antibodies (less likely to have side effects with
prolonged use) for HIV prevention, the new generation broadly
neutralizing antibodies (bNAb) to HIV-1 were also tested in this
system (Veselinovic et al., 2012). It was found that anti-HIV bNAb
VRC01 confers signiﬁcant protection against HIV-1 vaginal infec-
tion. Pointing to the beneﬁts of a combinatorial use of different
antibodies, it was shown that a four bNAb combination confers full
protection against vaginal challenge. BLT mice have also been
widely used to evaluate the efﬁcacy of various microbicide and
oral PrEP strategies (Denton and Garcia, 2012). The compounds
tested successfully in this system for microbicide potential include
tenofovir, emtricitabine, C52L, C5A, PIE12-Trimer, and TC247
(Denton et al., 2011). It was also found that a combination of
TDF and FTC given orally provided full protection against rectal
viral challenge (Denton et al., 2010). Current major research
questions in the HIV-PrEP ﬁeld are what pharmacologically effec-
tive concentrations of ARTs need to be reached in the mucosal
tissue for preventing HIV-1 sexual transmission and what combi-
nation of drugs will provide full protection. In this regard Hu-Mice
are likely to play an ever increasing important role in the near
future. While both the hu-HSC RG and BLT mice are shown to be
equally amicable for testing microbicide and oral PrEP strategies
against vaginal HIV-1 transmission, the latter received more
attention until recently due to its early application. However it is
worth noting that the hu-HSC RG model offers several advantages
due to its simplicity of preparation since no surgery is involved,
longer life span, lower cost and larger number of reconstituted
animals that can be generated per human tissue.Antiretroviral therapies for HIV-1
There are many advantages to evaluating anti-HIV therapies in
the new hu-Mice (Van Duyne et al., 2009). First, the chronic nature
of HIV-1 infection is replicated in these mice thus permitting long-
term drug evaluation and identiﬁcation of drug resistant mutants
that arise in vivo. Additionally, restoration of CD4þ T cell levels
resulting from effective treatment can be evaluated, since there is
continuous de novo hematopoiesis in these mice unlike in early hu-
Mouse models.
A number of studies evaluated combinations of ARTs to suppress
viral loads. Choudhary et al. tested a combination of RT inhibitors
emtricitabine and TDF together with a strand transfer inhibitor in
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reduction in viral loads with a concomitant rise in CD4þ T cells.
Treatment interruption resulted in viral rebound and renewed the
loss of helper CD4þ T cells, similar to that seen in human infection.
Furthermore, failure of HAART in some mice was determined to be
due to the emergence of drug resistant viruses. In this study PK-PD
aspects of these drugs were also successfully evaluated, establishing
the feasibility of such studies in this system. Thus many aspects of
HIV-ART can be studied in this system to derive important preclinical
data on new candidate drugs. Later studies that showed more
complete viral suppression in the context of identifying viral latency
used more intensiﬁed drug regimens that included AZT, lamivudine,
indinavir (Sango et al., 2010), AZT-Indinavir-didanosine (ddI)
(Marsden and Zack, 2010) and Tenofovir-Emtricitabine and raltegra-
vir (Denton et al., 2011). An emerging trend in HIV treatment is to
develop long-acting drugs so the number of doses can be reduced.
A recent report evaluated the efﬁcacy of a combination of two long
acting drug formulations, TMC278-LA and TMC-181-LA, together
with other formulations of 3TC and TDF (Nischang et al., 2012).
Emergence of drug resistant mutants was seen in insufﬁciently
treated mice and viral rebound was noted in treatment interrupted
mice, conﬁrming the presence of a latent reservoir.
In addition to small molecule drugs, other studies investigated
therapeutic strategies using novel molecules in hu-Mice. Van Duyne
et al. showed the efﬁcacy of tat peptide analogs in hu-HSC RG Mice
(Van Duyne et al., 2008). SiRNAs targeted to either viral (tat, rev
among others) or cellular (CCR5 or CXCR4) molecules have been
shown to have potent anti-HIV activity in many in vitro studies
(Kitchen et al., 2011). However, in vivo delivery presented chal-
lenges. A number of novel siRNA delivery strategies have recently
been successfully evaluated in hu-Mice, including dendrimer for-
mulated siRNA nanoparticles for improved cellular uptake (Zhou
et al., 2011), single chain antibodies binding to CD7 surface
molecule on lymphocytes (Kumar et al., 2008), and immunolipo-
somes targeted to LFA-1 integrin present on white blood cells
(Kim et al., 2010). While found to be effective in HIV-1 inhibition,
these strategies are not speciﬁc for drug delivery into HIV-1
infected cells. A novel approach exploited the speciﬁcity offered
by a gp120 aptamer which can bind to and be internalized by HIV-1
infected cells (Neff et al., 2011). This aptamer was conjugated to an
siRNA targeted to tat-rev transcripts, creating a dual-function
molecule with viral neutralization and replication inhibition capa-
cities. When HIV-1 viremic mice were treated with this chimeric
construct, there was drastic suppression of viral loads demonstrat-
ing the efﬁcacy of this strategy. Another set of useful molecules for
HIV-1 protection and therapy are broadly neutralizing anti-HIV
antibodies (Joseph et al., 2010). Their efﬁcacies have been recently
validated in the hu-Mouse system by deploying antibody producing
cellular ‘backpacks’ (Luo et al., 2010) or utilizing adeno-associated
virus vectors (Balazs et al., 2012).Gene therapy strategies for HIV-1
HIV-1-induced disease is an excellent target for novel gene
therapy approaches (Strayer et al., 2005; Rossi et al., 2007). Unlike
acute viral infections that progress rapidly, HIV/AIDS is chronic in
nature thus providing a long window of opportunity for genetic
manipulation of virus susceptible cells and protective effector
T cells. Moreover the virus susceptible cells are regenerated from a
stem cell source in the bone marrow. The critical cellular and viral
molecules necessary for viral entry and replication are known, and
several methods and techniques currently exist to disable their
function. For example, disrupting the viral co-receptors CCR5 and
CXCR4 by various methods, such as siRNAs or zinc ﬁnger nucleases,
can generate virus resistant cells not permissive to viral entry(Kitchen et al., 2011). For a long lasting therapy, genetic modiﬁcation
of hematopoietic stem cells holds the most promise since the
modiﬁed cells are expected to generate HIV-1 resistant cells for life,
providing effective immune reconstitution (Kiem et al., 2012). Early
evidence for the success of such an approach came from the SCID-hu
mouse studies in which retrovirally gene-transduced CD34þ HSC
were differentiated successfully into mature T cells expressing the
vector (Akkina et al., 1994). The new generation hu-Mouse models,
due to their long-lasting multilineage hematopoietic cell engraft-
ment, should prove to be far superior to test novel gene therapy
strategies. Indeed, many new approaches have been successfully
tested in these systems. Current methods center on inhibiting viral
entry, harnessing host restriction factors, disabling essential viral
regulatory molecules and fortifying host effector T cells for improved
antiviral effects (Kitchen et al., 2011; Kiem et al., 2012).
With regard to viral entry, it has been known for some time
that individuals lacking the CCR5 co-receptor due to the CCR5D32
mutation are relatively resistant to HIV-1 infection since nearly
all primary infecting viral strains use this co-receptor. Therefore
this is thought of as an attractive target for gene disruption
(Anderson et al., 2007). This is further substantiated by the
example of the so called ‘Berlin patient’ who has been cured from
active HIV infection following a bone marrow transplant consist-
ing of CCR5 null cells (Allers et al., 2011). Studies by Holt et al.
have shown that disruption of the CCR5 gene in CD34þ HSC by
zinc ﬁnger nucleases gave rise to HIV resistant cells in hu-HSC
mice (Holt et al., 2010). Similarly, Shimuzu et al. reported the
efﬁcacy of siRNA targeting the CCR5 gene delivered via a lentiviral
vector using the BLT mouse model (Shimizu et al., 2010). Other
studies reported the efﬁcacy of CXCR4 gene disruption in hu-Mice
(Wilen et al., 2011; Yuan et al., 2012). Ter Brake et al. used an
siRNA against HIV-1 nef gene delivered via lentiviral vector into
CD34þ HSC for evaluation in hu-Mice (ter Brake et al., 2009). It
was found that the differentiated siRNA transgenic cells showed
signiﬁcant protection against HIV-1 challenge ex vivo.
For long-term success of gene therapy it is necessary to
employ more than one anti-HIV gene to prevent the generation
of escape mutants. Using such an approach a combination of three
different genes, namely a tat-rev siRNA, tar decoy and an anti-
CCR5 ribozyme delivered via lentiviral vector into CD34þ cells
was initially tested in vivo in hu-Mice (Anderson et al., 2007).
Results from these hu-Mouse studies helped formulate a recently
conducted human clinical trial (DiGiusto et al., 2010). Along these
lines a combination of CCR5 siRNA, TAR decoy and a human/
rhesus macaque TRIM5 alpha isoform was also successfully tested
in hu-Mice (Walker et al., 2012). In a different approach, broadly
neutralizing antibodies have also been tested. In the studies of
Joseph et al., gene coding sequences for anti-HIV antibody 2G12
were transduced into CD34þ cells via a lentiviral vector in hu-
Mice (Joseph et al., 2010). HIV-1 challenge resulted in much lower
levels of viremia. Other novel strategies engineered T cells with
HIV-1 gag speciﬁc TCR with promising results (Kitchen et al.,
2012). As can be seen, humanized mice have permitted in vivo
testing of many novel gene therapy strategies that would other-
wise not be possible. Exploitation of these mice should provide
additional important pre-clinical data in the future, such as
addressing the number of dominant transgenic clonal cells that
engraft, their persistence and expression levels of the vector in
differentiated cells and ﬁnally the immune competence of the
transgenic HIV-1 resistant T cells and macrophages.HIV-1 related dementia
A high proportion of individuals with advanced immunodeﬁ-
ciency develop AIDS related dementia with associated mental
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inﬁltration, formation of microglial nodules and presence of multi-
nucleated giant cells. These changes, which disrupt neuronal net-
works, are attributed to viral and infected cellular products. HIV-1
infected hNSGmice have been evaluated to model the CNS pathology
(Gorantla et al., 2012). It was found that HIV-1 infection accelerated
the entry of activated HLA-DRþ lymphocytes and macrophages into
the brain. Viral spread to the brain was determined to be due to
infected cell migration crossing the blood brain barrier. The pathology
includes glial cell activation, meningitis and neuronal degeneration,
with virus positive cells being found in the meninges and perivas-
cular spaces. Prior CD8þ T cell depletion by antibody treatment in
infected mice led to accelerated disease progression with develop-
ment of meningitis and occasional meningoencephalitis, suggesting
that cellular immunity has a role in modulating CNS disease.
Additional evaluations by non-invasive longitudinal proton spectro-
scopic and diffusion tensor imaging, together with determination of
peripheral viral loads and T cell counts, revealed a sequential
development of neuronal abnormalities. Based on this data, hu-
Mice appear to be a good model to systematically evaluate the CNS
pathogenesis by HIV and to develop novel methods of treatment to
prevent/control dementia. Recently in this context, the use of long
acting nanoformulated ART given once a week elicited neuroprotec-
tive responses in HIV-1 infected hNSG mice, as evidenced by
increases in microtubule-associated protein-2 synaptophysin and
neuroﬁlament expression (Dash et al., 2012). These ﬁndings indicate
that therapies are possible and can be tested effectively using this
system.Dengue virus
Dengue (DEN) is a mosquito-borne viral disease affecting millions
of people every year (Halstead, 2008; Simmons et al., 2012). The
causative virus is a ﬂavivirus with four antigenically distinct ser-
otypes, DEN-1 through DEN-4. All dengue serotype viruses can infect
humans with equal efﬁciency causing a range of illnesses spanning
from subclinical infection to acute febrile dengue fever to the severe
and often fatal vascular leakage conditions of dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS). More commonly, the
severe DHF/DSS forms of the disease are believed to be due to
secondary infection of individuals who had previously recovered
from a primary dengue infection with a different serotype virus. This
is attributed to the antibody mediated immune enhancement
phenomenon. There are currently no licensed vaccines or effective
anti-viral treatments available for DENV, although many are in
development. Until recently a major impediment to the under-
standing of dengue virus pathogenesis and immunity was the lack
of an ideal animal model (Zompi and Harris, 2012). While primates
can be infected by DENV they do not exhibit symptoms of disease. In
addition they are expensive and use of large numbers of primates is
prohibitive. Interferon-deﬁcient mice with intact adaptive immunity
have been useful in the study of some aspects of pathogenesis and
protective immunity since they support virus replication followed by
death. Similarly, NOD-SCID mice engrafted with human cord blood
HSC were found to be susceptible to DENV infection and showed
fever and thrombocytopenia, signs typical of dengue infection (Bente
et al., 2005). However, a major deﬁciency of these human cell
engrafted models is the lack of a human immune response, thus
precluding any vaccine work or immunopathogenesis studies that
address the antibody dependant enhancement of infection. The ﬁrst
thorough evaluation of human immune responses was conducted by
Kuruvilla et al. using hu-HSC RGMice (Kuruvilla et al., 2007). Dengue
virus-infected hu-HSC RGmice showed viremia lasting up to 21 days
with generation of both IgM and IgG antibodies. While all the mice
produced IgM, only a subset produced IgG, consistent with inefﬁcientantibody class switching. This was also the ﬁrst study to demonstrate
generation of neutralizing human antibodies against any human
pathogen using hu-Mice. Later studies by Jaiswal et al. evaluated
dengue infection and immune responses in HLA-A2 transgenic hNSG
mice engrafted with matched cord blood. IgM antibody responses
were seen in infected mice, and human T cells produced IFN-g and
TNF-a in response to stimulation with dengue peptides, thus
indicating both cellular and humoral responses. The same group
extended these studies by using NSG-BLT mice and found that IgM
neutralizing antibodies were produced in addition to HLA-A2
restricted T cell responses, as measured by IFN-g secretion following
peptide stimulation (Jaiswal et al., 2012). Hu-HSC mice were also
successfully used to evaluate dengue viral insect transmission and
immune response (Cox et al., 2012). Using hu-HSC RG as well as BLT
mice, we also were able to achieve insect dengue transmission and
immune responses (Akkina et al., unpublished data). However, unlike
in the study above both i/p route and insect-bite acquired infections
resulted in antibody responses.Epstein-Barr virus
EBV is a widely spread herpesvirus that infects more than 90%
of the world’s population and causes persistent infection (Cohen,
2000; Young and Rickinson, 2004). While EBV is shown to infect
cotton top tamarins in an experimental setting, humans are the
primary host for this virus in nature. The medical importance is
due to its role in causing acute mononucleosis, lymphoprolifera-
tive disease (LPD) and in the development of a variety of
malignancies that include Burkitt’s Lymphoma, nasopharyngeal
carcinoma, and Hodgkin’s lymphoma. Following primary infec-
tion, as is typical with all human herpesviruses, EBV establishes
life-long latency. The immune system of the majority of indivi-
duals controls the infection via effector T cells, keeping the
development of malignancies in check. During lytic infection
more than 80 viral genes are expressed, while during malignancy
only latency-associated viral proteins are expressed (Ramer et al.,
2011). Eight latency associated EBV proteins are described: six
nuclear antigens (EBNAs) and two membrane proteins, LMP 1 and
2. Expression of these proteins varies depending on the type of
latency. Only EBNA1 is expressed in Burkitt’s lymphoma, a type I
latency. In Hodgkin’s lymphoma and nasopharyngeal carcinoma,
both type II latencies, either one or both LMP1 and 2 are
expressed in addition to EBNA1. In cancers arising in immuno-
compromised patients such as those with HIV or transplant
subjects, all the eight EBV latency proteins can be found, reﬂect-
ing latency type III. Thus EBV infection can vary between
individuals displaying complex pathogenesis. Use of hu-Mice for
EBV studies permitted evaluation of the infection and immune
response events (Ramer et al., 2011). Early studies using NOD-
SCID mice engrafted with human HSC and injection of EBV
established infection and LPD with expression of latency proteins
suggestive of type III latency (Islas-Ohlmayer et al., 2004). How-
ever, since these mice do not produce adequate numbers of
human T cells, their cellular responses could not be studied. The
development of hu-HSC RG mice with better human cell engraft-
ment and T cell generation helped model EBV infection and
immune responses more effectively. Infection with EBV resulted
in viral ampliﬁcation as well as T cell responses with an increase
in CD8þ T cells (Yajima et al., 2009). Conﬁrming in vivo priming, T
cells from infected mice cultured in vitro produced IFN-g in
response to stimulation with autologous lymphoblastoid cell
lines. Later studies using hNSG and BLT mice produced similar
results. EBV infection of hNSG mice follows a dose dependant
effect (Ramer et al., 2011). Low dose infection gave rise to
persistent asymptomatic infection and detectable T cell responses
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more vigorous T cell expansion. Higher doses viral challenge led
to tumor generation. Expanded T cells were of memory T cell
phenotype with protective capacity since depletion of T cells prior
to infection led to more rapid and disseminated LPD. Based on the
utility of this model for infection and immune response, more
advanced studies using EBV viral mutants were conducted using
hNSG mice. Infection with EBNA3B-knockout EBV mutant virus
showed more aggressive proliferation of B cells, generating
lymphomas resembling diffuse large B cell lymphomas (DLBCL)
(White et al., 2012). It was also found that while infection with
mutant EBV induced expansion of T cells, they failed to inﬁltrate
the tumor tissues unlike a wild type virus infection. This was
reasoned to be due to EBNA3B gene being a tumor suppressor and
also playing a role as a factor responsible for secretion of T cell
attracting chemokine CXCL10 (IP10).Hepatitis C virus
Hepatitis C virus is another major human speciﬁc pathogen
with a global public health concern with over 175 million people
currently infected. While a minority of infected individuals
(10–20%) spontaneously clear the virus due to an effective
immune response, chronic infection generally ensues in 80% of
patients often leading to hepatitis, liver ﬁbrosis, cirrhosis and the
eventual development of hepatocellular carcinoma in a subset of
patients. Chronic HCV infection is associated with impaired CD4þ
and CD8þ T cell functions, and therefore detailed studies of
immunopathogenesis are critical to fully understand disease
progression so preventive and therapeutic approaches can be
developed. While chimpanzees played an important role in HCV
studies, in addition to their cost and endangered status, other
limitations included low chronic infection rate and the absence of
hepatic ﬁbrosis. Therefore, a cost-effective small animal model
that permits HCV infection and immune responses would greatly
aid future progress (Washburn et al., 2011; Dorner et al., in press).
In this regard, hu-Mice that harbor functional human hepatocytes
could ﬁll this void. Indeed during the last decade a number of
murine–human hepatocyte chimeric models have been developed.
These include Alb-uPA-SCID mice and Fah-RG mice that permit
human hepatocyte engraftment (Meuleman et al., 2005; He et al.,
2010). While productive HCV infection with associated pathogen-
esis could be seen in these mice, lack of a functioning human
immune system precluded studies on immunopathogenesis which
plays a central role in progressive disease in chronically infected
individuals. This setback was recently rectiﬁed by the generation of
immunocompetent humanized mice that also harbor a functional
human hepatic system. This was achieved with mice on a RG
background by generating transgenic mice (AFC8 mice) that
express active Caspase 8 fused to FK506 binding domain (FKBP)
with inducible suicidal activity in murine hepatocytes under the
control of the albumin promoter. Human hepatocyte progenitor
cells, together with human HSC, were co-transplanted into these
mice which were then treated with FKBP dimeriser. Destruction of
native murine hepatocytes post-treatment allowed selective out-
growth of human hepatocytes, while human HSC engraftment
permitted the development of human immune cell subsets giving
rise to a AFC8-hu HSC/Hep mouse (simply termed as Hu-Liver-HSC
mouse here) (Washburn et al., 2011). HCV challenge of these mice
supported productive viral infection in engrafted human hepato-
cytes and generated viral speciﬁc T cell responses. Hepatitis and
ﬁbrotic lesions were seen correlating with activation of stellate
cells and human ﬁbrogenic gene expression. Whereas HCV viremia
could be seen in the previous uPA and Fah mouse models
(supporting 450% hepatocyte engraftment) it was not the casein this system due to lower levels of (15%) hepatocyte engraft-
ment thus suggesting further improvements are necessary. Never-
theless, the new chimeric APC8-hu HSC/Hep mouse system with a
capacity to support productive infection and immune response is
an important step forward in this area.Advantages and disadvantages of different hu-Mouse models
Based on the experimental needs and viruses used there are
advantages and disadvantages with the currently used new
hu-HSC and BLT mouse models. From a practical standpoint, the
hu-HSC model is relatively easy to create since only a quick, non-
surgical intrahepatic injection of HSC is needed. Human HSC from
easily procurable sources such as cord blood can be used and
larger cohorts of mice from a single donor can be made. Therefore
hu-HSC mice can be employed for large scale drug evaluations
and PrEP studies without much difﬁculty. A disadvantage with
this model however is the lack of proper human T cell restriction
due to the absence of a human thymus. Co-expression of HLA
class I and II genes by transgenesis will overcome this deﬁciency.
A particular advantage with the BLT mouse model is the presence
of transplanted human thymus, permitting proper T cell educa-
tion and restriction and facilitating T/B cell cooperation. Thus
these mice are preferable for vaccine and immunity studies.
Disadvantages include the need for complicated surgery to
implant human fetal tissues under the kidney capsule, and that
the number of mice that can be generated from a single fetal
donor tissue is limited. Scale-up of their production for large scale
experimentation and testing also poses challenges due to the
requirement for fetal tissues that are often difﬁcult to procure in
sufﬁcient quantities.Current limitations, advances and future prospects
Current human immunocompetent hu-Mouse models have
come a long way since the original description of human–
mouse chimeras. However, there are still several limitations that
need to be overcome (Shultz et al., 2011). These include residual
innate immunity in the immunodeﬁcient mouse strains requiring
irradiation and prior conditioning, less than ideal T cell numbers
and sub-optimal maturation of B cells, absence of human HLA
class I and class II restriction in hu-HSC mouse models and lack of
adequate levels of HLA APCs in the BLT mouse model, deﬁciencies
in T and B cell cooperation resulting in low levels of antibody
responses and inefﬁcient immunoglobulin class switch, and
poorly cross-reactive native murine growth factors and cytokines.
These deﬁciencies are currently being addressed and rectiﬁed. In
addition to T cells, B cell and NK cells, mouse macrophages are also
found to contribute to xenograft rejection in hu-Mice. Mouse
macrophages expressing native SIRPa receptor clear out xeno-
grafted human cells that do not express the cognate ligand CD47
(‘don‘t eat me’ marker of self) (Ide et al., 2007; van den Berg and van
der Schoot, 2008). Supporting their role in graft rejection, it has been
recently shown that human SIRPa transgenic mice exhibit improved
human cell reconstitution (Strowig et al., 2011). In a reverse
approach, human HSC stably transduced with murine CD47 ligand
by lentiviral vectors also showed increased engraftment (Legrand
et al., 2011). Rectifying CD47-SIRPa interactions in hu-Mice will lead
to more robust and lasting human cell engraftment. As pointed out
above, transgenic expression of human HLA-DR4 also led to
increased T cell numbers in reconstituted mice. Thus co-expression
of HLA class I and Class II in doubly transgenic mice is likely to
further improve human T cell reconstitution, T/B cell cooperation/
help and mediate HLA restricted immune responses (Garcia and
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human HLA Class I and Class II genes in mouse MHC loci will also
preclude the unwanted mouse H-2 restricted human cell immune
responses. Since many murine cytokines and growth factors are
poorly cross-reactive with their human counterparts thus resulting
in sub-optimal human cell development and maintenance, supplying
these in trans either by injection or by transgenesis can overcome
these deﬁciencies. Among these cytokines are GM-CSF, IL-4, M-CSF
for monocyte/macrophage, IL-7 for T cells, IL-15 for NK cells and EPO
for erythrocytes (Willinger et al., 2011). Knock-in replacement of
mouse cytokine genes with their human equivalents in appropriate
loci provides an additional advantage of their constitutive expression
operated by the mouse regulatory elements. Along these lines,
expression of human thrombopoietin resulted in higher human cell
engraftment and better HSC maintenance (Willinger et al., 2011)
whereas transgenic mice with human IL-3, GM-CSF (Willinger et al.,
2011) and M-CSF (Rongvaux et al., 2011) knock-in genes exhibited
improved myeloid differentiation and function, thus demonstrating
the beneﬁts of these strategies. Clearly, ongoing intensive work has
identiﬁed several areas for improving the existing human immuno-
competent hu-Mouse models. However, these different strategies
addressing cytokines, growth factors and HLA molecules need to
converge together to derive a composite recipient mouse strain
incorporating all the desirable attributes. Given the recent acceler-
ated progress, it is not too far in the future that superior
hu-Mouse models will become available.Acknowledgments
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